Limits...
Bupropion for interferon-alpha-induced depression in patients with hepatitis C viral infection: an open-label study.

Chen WC, Lai HC, Su WP, Palani M, Su KP - Psychiatry Investig (2015)

Bottom Line: Bupropion, a commonly used antidepressant agent, has recently found to have strong anti-inflammatory effects in animal models.In addition, 5 patients had 50% decreases in NRS for neuropsychiatric symptoms.This preliminary open-label study suggests that bupropion is effective in treating IFN-alpha-induced depressive and somatic symptoms.

View Article: PubMed Central - PubMed

Affiliation: Department of Psychiatry and Mind-Body Interface Laboratory (MBI-Lab), China Medical University Hospital, Taichung, Taiwan.

ABSTRACT
Interferon (IFN)-α therapy for chronic hepatitis C virus (HCV) infection is frequently associated with major depressive episodes. Bupropion, a commonly used antidepressant agent, has recently found to have strong anti-inflammatory effects in animal models. Despite of the theoretical relevancy, the antidepressant effect of bupropion in IFN-alpha-induced depression has never been studied. Ten HCV patients with IFN-α-induced depression were recruited to receive 8-week bupropion treatment and were assessed every 2 weeks for depressive symptoms by the Hamilton rating scale for depression (HAMD) and somatic symptoms by the Neurotoxicity Rating Scale (NRS). Four of the 10 patients met the criteria for remission (total HAMD scores≤7), and 5 patients met the criteria for response (at least 50% reduction in total HAMD scores). In addition, 5 patients had 50% decreases in NRS for neuropsychiatric symptoms. This preliminary open-label study suggests that bupropion is effective in treating IFN-alpha-induced depressive and somatic symptoms.

No MeSH data available.


Related in: MedlinePlus

The rates of response and remission in 10 hepatitis C viral infected patients receiving bupropion therapy for interferon-alpha-induced depression at visits of weeks 0, 4, and 8.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4310912&req=5

Figure 1: The rates of response and remission in 10 hepatitis C viral infected patients receiving bupropion therapy for interferon-alpha-induced depression at visits of weeks 0, 4, and 8.

Mentions: Ten patients who agreed to receive bupropion treatment were recruited in this study. Table 1 shows the demographics, clinical characteristics, virological response, and the efficacies and adverse effects of bupropion treatment. After bupropion therapy for 8 weeks, 4 (of 10) patients met the criteria for remission (total scores less than or equal to 7), and 5 patients met the criteria for response (at least 50% reduction in total scores). Four of the 10 patients had a 50% decrease in the CFQ for fatigue symptoms, and 5 patients had 50% decrease in NRS for neuropsychiatric symptoms. Figure 1 illustrates the rates of responders and remitters at visits of weeks 0, 4, and 8.


Bupropion for interferon-alpha-induced depression in patients with hepatitis C viral infection: an open-label study.

Chen WC, Lai HC, Su WP, Palani M, Su KP - Psychiatry Investig (2015)

The rates of response and remission in 10 hepatitis C viral infected patients receiving bupropion therapy for interferon-alpha-induced depression at visits of weeks 0, 4, and 8.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4310912&req=5

Figure 1: The rates of response and remission in 10 hepatitis C viral infected patients receiving bupropion therapy for interferon-alpha-induced depression at visits of weeks 0, 4, and 8.
Mentions: Ten patients who agreed to receive bupropion treatment were recruited in this study. Table 1 shows the demographics, clinical characteristics, virological response, and the efficacies and adverse effects of bupropion treatment. After bupropion therapy for 8 weeks, 4 (of 10) patients met the criteria for remission (total scores less than or equal to 7), and 5 patients met the criteria for response (at least 50% reduction in total scores). Four of the 10 patients had a 50% decrease in the CFQ for fatigue symptoms, and 5 patients had 50% decrease in NRS for neuropsychiatric symptoms. Figure 1 illustrates the rates of responders and remitters at visits of weeks 0, 4, and 8.

Bottom Line: Bupropion, a commonly used antidepressant agent, has recently found to have strong anti-inflammatory effects in animal models.In addition, 5 patients had 50% decreases in NRS for neuropsychiatric symptoms.This preliminary open-label study suggests that bupropion is effective in treating IFN-alpha-induced depressive and somatic symptoms.

View Article: PubMed Central - PubMed

Affiliation: Department of Psychiatry and Mind-Body Interface Laboratory (MBI-Lab), China Medical University Hospital, Taichung, Taiwan.

ABSTRACT
Interferon (IFN)-α therapy for chronic hepatitis C virus (HCV) infection is frequently associated with major depressive episodes. Bupropion, a commonly used antidepressant agent, has recently found to have strong anti-inflammatory effects in animal models. Despite of the theoretical relevancy, the antidepressant effect of bupropion in IFN-alpha-induced depression has never been studied. Ten HCV patients with IFN-α-induced depression were recruited to receive 8-week bupropion treatment and were assessed every 2 weeks for depressive symptoms by the Hamilton rating scale for depression (HAMD) and somatic symptoms by the Neurotoxicity Rating Scale (NRS). Four of the 10 patients met the criteria for remission (total HAMD scores≤7), and 5 patients met the criteria for response (at least 50% reduction in total HAMD scores). In addition, 5 patients had 50% decreases in NRS for neuropsychiatric symptoms. This preliminary open-label study suggests that bupropion is effective in treating IFN-alpha-induced depressive and somatic symptoms.

No MeSH data available.


Related in: MedlinePlus